Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
vasopressin analogues	817	16679-58-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: desmopressin acetate hydrate minirinmelt desmopressin adiuretin minirin desmopressin acetate DDAVP	A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR. Molecular weight: 1069.22 Formula: C46H64N14O12S2 CLOGP: -2.31 LIPINSKI: 3 HAC: 26 HDO: 14 TPSA: 435.41 ALOGS: -3.99 ROTB: 19 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

desmopressin acetate hydrate
minirinmelt
desmopressin
adiuretin
minirin
desmopressin acetate
DDAVP

A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR.

Molecular weight: 1069.22
Formula: C46H64N14O12S2
CLOGP: -2.31
LIPINSKI: 3
HAC: 26
HDO: 14
TPSA: 435.41
ALOGS: -3.99
ROTB: 19

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
25	mcg	N
0.40	mg	O
4	mcg	P
0.24	mg	SL

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	47 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.00 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	0.12 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.30 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.40 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	3 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.10 mg/mL	Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Confidence	Similarity
kinase-safety-class	ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK	17
kinase-selectivity-class	GRK2	1
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	1.242	High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
June 18, 2019	PMDA	FERRING PHARMACEUTICALS CO., LTD.
Feb. 21, 1978	FDA	FERRING PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyponatraemia	753.31	17.75	310	6886	133228	90488023
Hyponatraemic encephalopathy	176.54	17.75	29	7167	277	90620974
Hypernatraemia	136.31	17.75	44	7152	9343	90611908
Craniopharyngioma	119.35	17.75	19	7177	146	90621105
Seizure	117.38	17.75	97	7099	152532	90468719
Hyponatraemic seizure	110.34	17.75	21	7175	489	90620762
Water intoxication	107.26	17.75	21	7175	570	90620681
Recalled product administered	100.52	17.75	21	7175	794	90620457
Cerebral salt-wasting syndrome	85.57	17.75	15	7181	217	90621034
Diabetes insipidus	85.36	17.75	24	7172	3188	90618063
Blood sodium decreased	75.55	17.75	39	7157	27574	90593677
Poor quality product administered	67.33	17.75	21	7175	3987	90617264
Pharyngeal haemorrhage	58.82	17.75	13	7183	643	90620608
Adrenocortical insufficiency acute	58.21	17.75	17	7179	2584	90618667
Renal salt-wasting syndrome	57.61	17.75	12	7184	447	90620804
Polyuria	51.82	17.75	22	7174	10018	90611233
Tonsillar disorder	50.99	17.75	13	7183	1189	90620062
Brain injury	50.30	17.75	20	7176	7718	90613533
Patent ductus arteriosus	48.78	17.75	17	7179	4552	90616699
Lethargy	46.10	17.75	39	7157	63100	90558151
Somnolence	44.67	17.75	68	7128	209016	90412235
Electrolyte imbalance	44.15	17.75	26	7170	23719	90597532
Premature baby	42.84	17.75	26	7170	25051	90596200
Urine output increased	41.57	17.75	12	7184	1750	90619501
Product prescribing error	40.86	17.75	27	7169	30118	90591133
Brain oedema	40.32	17.75	22	7174	17363	90603888
Drug interaction	39.30	17.75	75	7121	276378	90344873
Osmotic demyelination syndrome	37.92	17.75	10	7186	1044	90620207
Oesophageal disorder	36.47	17.75	12	7184	2701	90618550
Puncture site haematoma	35.83	17.75	6	7190	65	90621186
Labelled drug-disease interaction medication error	35.27	17.75	7	7189	204	90621047
Blood sodium increased	34.59	17.75	12	7184	3170	90618081
Hypopituitarism	32.89	17.75	10	7186	1743	90619508
Cutaneous lupus erythematosus	30.99	17.75	11	7185	3107	90618144
Puncture site haemorrhage	30.84	17.75	7	7189	391	90620860
Foetal exposure during pregnancy	30.25	17.75	26	7170	42949	90578302
Exposure during pregnancy	29.43	17.75	61	7135	238349	90382902
Hallucination	29.41	17.75	31	7165	65928	90555323
Nephrogenic diabetes insipidus	29.23	17.75	8	7188	962	90620289
Hepatitis toxic	29.08	17.75	11	7185	3714	90617537
Haemorrhagic disorder	28.89	17.75	8	7188	1004	90620247
Hypoosmolar state	28.71	17.75	6	7190	227	90621024
Mood altered	27.30	17.75	17	7179	17127	90604124
Acromegaly	27.04	17.75	5	7191	99	90621152
Joint swelling	26.85	17.75	4	7192	503296	90117955
Gastrointestinal infection	25.74	17.75	14	7182	10976	90610275
Blood sodium abnormal	25.65	17.75	7	7189	832	90620419
Scleroderma-like reaction	25.31	17.75	5	7191	142	90621109
Oligohydramnios	25.11	17.75	12	7184	7189	90614062
Thoracotomy	24.98	17.75	4	7192	32	90621219
Headache	24.71	17.75	134	7062	862612	89758639
Generalised tonic-clonic seizure	24.32	17.75	21	7175	34882	90586369
Urine output decreased	23.95	17.75	14	7182	12589	90608662
Neoplasm recurrence	23.21	17.75	9	7187	3250	90618001
Pituitary tumour benign	23.02	17.75	8	7188	2124	90619127
Premature delivery	22.43	17.75	21	7175	38741	90582510
Abortion induced	22.05	17.75	13	7183	11875	90609376
Diabetes with hyperosmolarity	22.03	17.75	3	7193	6	90621245
Germ cell cancer	21.94	17.75	4	7192	73	90621178
Multiple-drug resistance	21.31	17.75	11	7185	7765	90613486
Encephalopathy	21.00	17.75	22	7174	46422	90574829
Drug intolerance	20.80	17.75	5	7191	447586	90173665
Urine sodium increased	20.67	17.75	4	7192	102	90621149
Thirst	20.65	17.75	14	7182	16281	90604970
Insulin-like growth factor increased	20.19	17.75	6	7190	968	90620283
Insulin-like growth factor decreased	20.18	17.75	5	7191	407	90620844
Hypophagia	19.89	17.75	19	7177	35918	90585333
Hepatic enzyme increased	18.92	17.75	3	7193	360733	90260518
Nasal discomfort	18.60	17.75	9	7187	5539	90615712
Epistaxis	18.59	17.75	28	7168	85097	90536154
Glucose tolerance impaired	18.22	17.75	10	7186	7975	90613276
Hypoglycaemia	18.22	17.75	25	7171	69823	90551428
Arterial haemorrhage	18.08	17.75	7	7189	2516	90618735

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyponatraemia	521.73	17.78	281	7061	101181	42512812
Craniopharyngioma	145.32	17.78	27	7315	239	42613754
Mechanical ventilation complication	97.80	17.78	23	7319	681	42613312
Water intoxication	92.54	17.78	20	7322	400	42613593
Diabetes insipidus	86.14	17.78	30	7312	3683	42610310
Osmotic demyelination syndrome	84.64	17.78	22	7320	990	42613003
Haemothorax	79.62	17.78	31	7311	5205	42608788
Inspiratory capacity decreased	72.80	17.78	25	7317	2942	42611051
Chorioretinopathy	71.22	17.78	21	7321	1510	42612483
Hypernatraemia	69.10	17.78	34	7308	9998	42603995
Hyponatraemic encephalopathy	63.69	17.78	11	7331	61	42613932
Head titubation	63.46	17.78	15	7327	454	42613539
Adverse reaction	58.45	17.78	23	7319	3970	42610023
Face oedema	56.55	17.78	33	7309	13633	42600360
Labelled drug-disease interaction medication error	55.63	17.78	11	7331	139	42613854
Shock haemorrhagic	53.78	17.78	34	7308	16208	42597785
Hypovolaemia	53.60	17.78	30	7312	11455	42602538
Angiopathy	51.84	17.78	23	7319	5354	42608639
Seizure	47.55	17.78	79	7263	120482	42493511
Epistaxis	45.84	17.78	57	7285	66769	42547224
Cogwheel rigidity	43.50	17.78	15	7327	1786	42612207
Emphysema	42.27	17.78	26	7316	11809	42602184
Apnoeic attack	42.08	17.78	11	7331	506	42613487
Hyponatraemic seizure	41.78	17.78	9	7333	177	42613816
Inappropriate antidiuretic hormone secretion	41.18	17.78	29	7313	16512	42597481
Epilepsy	39.26	17.78	34	7308	26137	42587856
Germ cell cancer	39.24	17.78	8	7334	119	42613874
Simple partial seizures	38.91	17.78	10	7332	430	42613563
Polyuria	38.34	17.78	23	7319	9988	42604005
Hypopituitarism	37.10	17.78	15	7327	2776	42611217
Anaphylactic reaction	36.84	17.78	41	7301	42702	42571291
Renal salt-wasting syndrome	34.57	17.78	9	7333	407	42613586
Extrapyramidal disorder	32.35	17.78	25	7317	16387	42597606
Haemorrhage	31.29	17.78	45	7297	60518	42553475
Neoplasm recurrence	30.66	17.78	13	7329	2711	42611282
Tachycardia	30.53	17.78	59	7283	101028	42512965
Sedation complication	29.80	17.78	13	7329	2906	42611087
Insulin-like growth factor increased	29.63	17.78	11	7331	1620	42612373
Anaphylactic shock	28.30	17.78	27	7315	23490	42590503
Insulin-like growth factor decreased	27.97	17.78	7	7335	270	42613723
Duplicate therapy error	27.51	17.78	7	7335	289	42613704
Epiphysiolysis	27.43	17.78	6	7336	127	42613866
Flatulence	26.77	17.78	27	7315	25125	42588868
Pneumothorax	26.40	17.78	26	7316	23517	42590476
Serotonin syndrome	26.15	17.78	27	7315	25818	42588175
Reaction to excipient	26.12	17.78	8	7334	654	42613339
Recalled product administered	25.41	17.78	8	7334	717	42613276
Hyperadrenocorticism	25.18	17.78	6	7336	188	42613805
Pharyngeal haemorrhage	24.59	17.78	8	7334	796	42613197
Polydipsia	24.47	17.78	13	7329	4475	42609518
Perforation	23.79	17.78	7	7335	499	42613494
Adrenocortical insufficiency acute	23.05	17.78	10	7332	2205	42611788
Nephrogenic diabetes insipidus	22.80	17.78	9	7333	1565	42612428
Blood sodium increased	22.43	17.78	11	7331	3207	42610786
Subcutaneous emphysema	22.08	17.78	9	7333	1700	42612293
Urine osmolarity increased	21.84	17.78	5	7337	131	42613862
Hypersensitivity	21.54	17.78	42	7300	72328	42541665
CNS germinoma	20.92	17.78	3	7339	3	42613990
Implant site pruritus	20.92	17.78	3	7339	3	42613990
Compulsive shopping	20.03	17.78	6	7336	455	42613538
Tracheal injury	19.85	17.78	4	7338	56	42613937
Urinary retention	19.82	17.78	30	7312	42184	42571809
Urinary tract infection	19.75	17.78	49	7293	99235	42514758
Anticholinergic syndrome	19.28	17.78	8	7334	1581	42612412
Akathisia	18.61	17.78	15	7327	10436	42603557
Toxic neuropathy	18.52	17.78	6	7336	589	42613404
Hypothalamo-pituitary disorder	18.46	17.78	7	7335	1093	42612900
Pollakiuria	18.38	17.78	21	7321	22484	42591509
Flushing	18.37	17.78	27	7315	37001	42576992

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyponatraemia	1163.53	15.35	542	12102	217111	110359544
Hyponatraemic encephalopathy	217.75	15.35	38	12606	360	110576295
Craniopharyngioma	206.29	15.35	36	12608	341	110576314
Hypernatraemia	190.44	15.35	73	12571	17760	110558895
Water intoxication	178.56	15.35	37	12607	922	110575733
Seizure	155.64	15.35	157	12487	221028	110355627
Diabetes insipidus	152.39	15.35	48	12596	6522	110570133
Hyponatraemic seizure	146.29	15.35	30	12614	709	110575946
Osmotic demyelination syndrome	120.51	15.35	31	12613	2032	110574623
Mechanical ventilation complication	105.09	15.35	23	12621	748	110575907
Renal salt-wasting syndrome	91.09	15.35	21	12623	867	110575788
Polyuria	90.42	15.35	43	12601	17695	110558960
Recalled product administered	88.41	15.35	22	12622	1260	110575395
Haemothorax	86.73	15.35	32	12612	6999	110569656
Inspiratory capacity decreased	86.17	15.35	25	12619	2570	110574085
Pharyngeal haemorrhage	81.48	15.35	21	12623	1386	110575269
Labelled drug-disease interaction medication error	79.19	15.35	16	12628	350	110576305
Cerebral salt-wasting syndrome	76.30	15.35	15	12629	284	110576371
Adrenocortical insufficiency acute	72.95	15.35	25	12619	4415	110572240
Germ cell cancer	68.67	15.35	13	12631	200	110576455
Blood sodium decreased	64.27	15.35	45	12599	38274	110538381
Hypopituitarism	61.69	15.35	22	12622	4368	110572287
Epistaxis	58.02	15.35	73	12571	130299	110446356
Hypovolaemia	54.95	15.35	33	12611	21641	110555014
Angiopathy	53.34	15.35	24	12620	8706	110567949
Nephrogenic diabetes insipidus	53.12	15.35	17	12627	2428	110574227
Shock haemorrhagic	52.82	15.35	35	12609	27212	110549443
Urine output increased	50.94	15.35	17	12627	2769	110573886
Neoplasm recurrence	50.81	15.35	20	12624	5212	110571443
Inappropriate antidiuretic hormone secretion	50.45	15.35	37	12607	33814	110542841
Poor quality product administered	49.53	15.35	19	12625	4622	110572033
Brain injury	49.04	15.35	26	12618	13450	110563205
Face oedema	46.33	15.35	35	12609	33434	110543221
Blood sodium increased	46.32	15.35	19	12625	5504	110571151
Product prescribing error	42.68	15.35	40	12604	51291	110525364
Apnoeic attack	41.62	15.35	11	12633	801	110575854
Drug interaction	40.13	15.35	137	12507	500046	110076609
Emphysema	39.81	15.35	26	12618	19730	110556925
Tonsillar disorder	39.24	15.35	12	12632	1477	110575178
Chorioretinopathy	38.01	15.35	13	12631	2282	110574373
Haemorrhage	35.66	15.35	52	12592	106640	110470015
Simple partial seizures	34.48	15.35	10	12634	1026	110575629
Joint swelling	34.14	15.35	5	12639	442840	110133815
Drug dose omission by device	33.97	15.35	21	12623	14495	110562160
Lethargy	33.31	15.35	47	12597	93529	110483126
Pneumothorax	32.26	15.35	29	12615	35256	110541399
Head titubation	31.82	15.35	10	12634	1347	110575308
Polydipsia	31.31	15.35	16	12628	7672	110568983
Electrolyte imbalance	31.06	15.35	29	12615	36999	110539656
Oesophageal disorder	30.74	15.35	12	12632	3058	110573597
Flushing	30.67	15.35	48	12596	104688	110471967
Urine osmolarity decreased	30.02	15.35	6	12638	124	110576531
Epilepsy	29.45	15.35	46	12598	100163	110476492
Epiphysiolysis	28.42	15.35	6	12638	164	110576491
Drug intolerance	28.26	15.35	6	12638	406506	110170149
Oligohydramnios	27.69	15.35	12	12632	3982	110572673
Duplicate therapy error	27.62	15.35	7	12637	432	110576223
Thoracotomy	27.60	15.35	6	12638	189	110576466
Pain	27.24	15.35	42	12602	954913	109621742
Insulin-like growth factor increased	26.67	15.35	10	12634	2286	110574369
Flatulence	26.09	15.35	31	12613	52118	110524537
Cutaneous lupus erythematosus	25.89	15.35	11	12633	3477	110573178
Puncture site haematoma	25.56	15.35	6	12638	268	110576387
Drug hypersensitivity	25.52	15.35	10	12634	454080	110122575
Hyperadrenocorticism	25.41	15.35	7	12637	596	110576059
Insulin-like growth factor decreased	25.30	15.35	7	12637	606	110576049
Urine osmolarity increased	25.02	15.35	6	12638	294	110576361
Adverse reaction	24.48	15.35	23	12621	29571	110547084
Puncture site haemorrhage	24.07	15.35	7	12637	725	110575930
Rheumatoid arthritis	23.99	15.35	3	12641	299610	110277045
Tachycardia	23.59	15.35	68	12576	226577	110350078
Acromegaly	23.33	15.35	5	12639	147	110576508
Anaphylactic shock	23.13	15.35	29	12615	51517	110525138
Contraindicated product prescribed	23.09	15.35	9	12635	2284	110574371
Hypoosmolar state	23.03	15.35	6	12638	413	110576242
Arthropathy	22.73	15.35	3	12641	287519	110289136
Mood altered	22.42	15.35	19	12625	21356	110555299
Hallucination	22.41	15.35	41	12603	101391	110475264
Abortion induced	22.40	15.35	13	12631	8006	110568649
CNS germinoma	22.15	15.35	3	12641	3	110576652
Cogwheel rigidity	22.06	15.35	10	12634	3688	110572967
Subcutaneous emphysema	22.05	15.35	9	12635	2575	110574080
Urine output decreased	21.53	15.35	18	12626	19858	110556797
Urine sodium increased	21.33	15.35	5	12639	222	110576433
Scleroderma-like reaction	21.31	15.35	5	12639	223	110576432
Hypothalamo-pituitary disorder	21.21	15.35	9	12635	2837	110573818
Pituitary tumour benign	21.21	15.35	9	12635	2838	110573817
Vascular stent thrombosis	20.93	15.35	10	12634	4151	110572504
Astrocytoma	20.66	15.35	5	12639	255	110576400
Arthralgia	20.61	15.35	36	12608	779596	109797059
Urinary retention	20.48	15.35	32	12612	69651	110507004
Reaction to excipient	20.45	15.35	8	12636	2051	110574604
Hepatitis toxic	20.35	15.35	11	12633	5910	110570745
Anaphylactic reaction	20.14	15.35	42	12602	114258	110462397
Blood sodium abnormal	19.76	15.35	7	12637	1363	110575292
Akathisia	19.59	15.35	16	12628	17097	110559558
Extrapyramidal disorder	19.35	15.35	20	12624	28847	110547808
Somnolence	19.19	15.35	76	12568	297373	110279282
Generalised tonic-clonic seizure	18.77	15.35	27	12617	54653	110522002
Headache	18.74	15.35	168	12476	882209	109694446
Off label use	18.74	15.35	257	12387	1499928	109076727
Dyspnoea	18.40	15.35	65	12579	1106807	109469848
Thirst	18.20	15.35	17	12627	21690	110554965
Hepatic enzyme increased	18.13	15.35	7	12637	320885	110255770
Completed suicide	18.07	15.35	3	12641	242378	110334277
Gastrointestinal infection	17.96	15.35	14	12630	13991	110562664
Perforation	17.86	15.35	7	12637	1803	110574852
Haemorrhagic disorder	17.85	15.35	7	12637	1806	110574849
Overdose	17.80	15.35	63	12581	233731	110342924
Melanoderma	17.72	15.35	5	12639	465	110576190
Swelling	17.72	15.35	9	12635	351032	110225623
Infusion related reaction	17.48	15.35	11	12633	381151	110195504
Foetal growth restriction	17.42	15.35	8	12636	3042	110573613
Labelled drug-drug interaction medication error	17.33	15.35	19	12625	29283	110547372
Wound	17.26	15.35	3	12641	234434	110342221
Wheezing	17.26	15.35	4	12640	255226	110321429
Diabetes with hyperosmolarity	17.23	15.35	3	12641	28	110576627
Nasal discomfort	17.21	15.35	10	12634	6171	110570484
Toxic neuropathy	17.20	15.35	6	12638	1117	110575538
Drug ineffective	17.19	15.35	256	12388	1520284	109056371
Metastases to pituitary gland	16.86	15.35	3	12641	32	110576623
Treatment noncompliance	16.75	15.35	30	12614	72960	110503695
Premature delivery	16.64	15.35	19	12625	30613	110546042
Dihydrotestosterone increased	16.11	15.35	3	12641	42	110576613
Tracheal injury	16.01	15.35	4	12640	233	110576422
Glossodynia	16.00	15.35	3	12641	222001	110354654
Aggression	15.77	15.35	26	12618	59184	110517471
Arterial haemorrhage	15.70	15.35	8	12636	3811	110572844
Hyperthermia malignant	15.55	15.35	8	12636	3892	110572763
Urinary tract infection	15.45	15.35	76	12568	326206	110250449
Pollakiuria	15.43	15.35	22	12622	44173	110532482

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	H01BA02	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES POSTERIOR PITUITARY LOBE HORMONES Vasopressin and analogues
FDA CS	M0022562	Vasopressins
MeSH PA	D003029	Coagulants
MeSH PA	D006401	Hematologic Agents
MeSH PA	D006490	Hemostatics
MeSH PA	D045283	Natriuretic Agents
MeSH PA	D050034	Antidiuretic Agents
CHEBI has role	CHEBI:33295	diagnostic agent
CHEBI has role	CHEBI:35480	analgesic
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:35674	antihypertensive agent
CHEBI has role	CHEBI:35846	renal agent
CHEBI has role	CHEBI:59727	vasopressin receptor agonist
FDA EPC	N0000175905	Vasopressin Analog
FDA PE	N0000175914	Increased Coagulation Factor VIII Activity
FDA PE	N0000175915	Increased Coagulation Factor VIII Concentration
FDA EPC	N0000175916	Factor VIII Activator
CHEBI has role	CHEBI:77715	nasal decongestant

Related Drugs by ATC class:

H01BA Vasopressin and analogues 4 drugs

lypressin ornipressin terlipressin vasopressin

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Nocturnal enuresis	indication	8009008
Hereditary factor VIII deficiency disease	indication	28293008	DOID:12134
Polyuria	indication	28442001
von Willebrand disorder	indication	128105004	DOID:12531
Partial Central Diabetes Insipidus	indication
Uremic Bleeding Tendency	off-label use
Psychogenic polydipsia	contraindication	15945005
Hypertensive disorder	contraindication	38341003	DOID:10763
Chronic heart failure	contraindication	48447003
Upper respiratory infection	contraindication	54150009
Allergic rhinitis	contraindication	61582004
Nasal discharge	contraindication	64531003
Nasal congestion	contraindication	68235000
Water intoxication syndrome	contraindication	71785001
Hyponatremia	contraindication	89627008
Cystic fibrosis	contraindication	190905008	DOID:1485
Impaired renal function disorder	contraindication	197663003
Finding of excessive fluid intake	contraindication	267026004
Hereditary von Willebrand disease type 2B	contraindication	359717002
Disorder of coronary artery	contraindication	414024009
Severe Allergic Rhinitis	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.65	acidic
pKa2	12.27	acidic
pKa3	12.64	acidic
pKa4	12.94	acidic
pKa5	13.39	acidic
pKa6	13.43	acidic
pKa7	13.8	acidic
pKa8	10.75	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
0.0277MG	NOCDURNA	FERRING PHARMS INC	N022517	June 21, 2018	DISCN	TABLET	SUBLINGUAL	11020448	May 21, 2029	TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENTS SERUM SODIUM CONCENTRATION
0.0277MG	NOCDURNA	FERRING PHARMS INC	N022517	June 21, 2018	DISCN	TABLET	SUBLINGUAL	11963995	May 21, 2029	TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENTS SERUM SODIUM CONCENTRATION
0.0553MG	NOCDURNA	FERRING PHARMS INC	N022517	June 21, 2018	DISCN	TABLET	SUBLINGUAL	10137167	May 21, 2029	TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENTS SERUM SODIUM CONCENTRATION
0.0553MG	NOCDURNA	FERRING PHARMS INC	N022517	June 21, 2018	DISCN	TABLET	SUBLINGUAL	11963995	May 21, 2029	TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENTS SERUM SODIUM CONCENTRATION
0.0277MG	NOCDURNA	FERRING PHARMS INC	N022517	June 21, 2018	DISCN	TABLET	SUBLINGUAL	9974826	April 13, 2030	TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
0.0553MG	NOCDURNA	FERRING PHARMS INC	N022517	June 21, 2018	DISCN	TABLET	SUBLINGUAL	9974826	April 13, 2030	TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENTS SERUM SODIUM CONCENTRATION
0.00083MG/SPRAY	NOCTIVA	ACERUS PHARMS	N201656	March 3, 2017	DISCN	SPRAY, METERED	NASAL	11419914	June 15, 2030	TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS WHO AWAKEN AT LEAST 2 TIMES PER NIGHT TO VOID BY INDUCING AN ANTIDIURETIC EFFECT BY INTRANASALLY ADMINISTERING A PLUME OF DROPLETS COMPRISING A DOSE OF ABOUT 0.05-5 MCG DESMOPRESSIN
0.00083MG/SPRAY	NOCTIVA	ACERUS PHARMS	N201656	March 3, 2017	DISCN	SPRAY, METERED	NASAL	12090190	June 15, 2030	TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS WHO AWAKEN AT LEAST 2 TIMES PER NIGHT TO VOID BY INTRANASALLY ADMINISTERING A PLUME OF DROPLETS COMPRISING A DOSE OF 0.75 MCG OR 1.5 MCG DESMOPRESSIN
0.00166MG/SPRAY	NOCTIVA	ACERUS PHARMS	N201656	March 3, 2017	DISCN	SPRAY, METERED	NASAL	11419914	June 15, 2030	TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS WHO AWAKEN AT LEAST 2 TIMES PER NIGHT TO VOID BY INDUCING AN ANTIDIURETIC EFFECT BY INTRANASALLY ADMINISTERING A PLUME OF DROPLETS COMPRISING A DOSE OF ABOUT 0.05-5 MCG DESMOPRESSIN
0.00166MG/SPRAY	NOCTIVA	ACERUS PHARMS	N201656	March 3, 2017	DISCN	SPRAY, METERED	NASAL	12090190	June 15, 2030	TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS WHO AWAKEN AT LEAST 2 TIMES PER NIGHT TO VOID BY INTRANASALLY ADMINISTERING A PLUME OF DROPLETS COMPRISING A DOSE OF 0.75 MCG OR 1.5 MCG DESMOPRESSIN
0.05MG/ML	DESMODA	ETON	N219873	Feb. 25, 2026	RX	SOLUTION	ORAL	12343372	April 3, 2044	MANAGEMENT OF CENTRAL DIABETES INSIPIDUS AS ANTIDIURETIC REPLACEMENT THERAPY FOR ADULTS AND PEDIATRIC PATIENTS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Vasopressin V2 receptor	GPCR	P30518	V2R_HUMAN	AGONIST	Ki	8.30	CHEMBL	SCIENTIFIC LITERATURE
Vasopressin V1b receptor	GPCR	P47901	V1BR_HUMAN		Ki	9.43	CHEMBL
Oxytocin receptor	GPCR	P30559	OXYR_HUMAN	AGONIST	Ki	7.60	IUPHAR
Vasopressin V1a receptor	GPCR	P37288	V1AR_HUMAN		Ki	8.42	CHEMBL
Oxytocin receptor	GPCR		OXYR_RAT		Ki	9.01	CHEMBL
Vasopressin V1a receptor	GPCR		V1AR_RAT		Ki	7.97	CHEMBL
Vasopressin V1b receptor	GPCR		V1BR_RAT		Ki	9.70	CHEMBL
Vasopressin V2 receptor	GPCR		V2R_RAT		Ki	9.10	CHEMBL

External reference:

ID	Source
4019709	VUID
N0000170340	NUI
D00291	KEGG_DRUG
62357-86-2	SECONDARY_CAS_RN
203658	RXNORM
4018750	VANDF
4019709	VANDF
C0011701	UMLSCUI
CHEBI:4450	CHEBI
CHEMBL1429	ChEMBL_ID
CHEMBL1200556	ChEMBL_ID
DB00035	DRUGBANK_ID
2182	IUPHAR_LIGAND_ID
3799	INN_ID
ENR1LLB0FP	UNII
5311065	PUBCHEM_CID
1069	MMSL
4548	MMSL
48087	MMSL
772	MMSL
d00583	MMSL
002125	NDDF
004784	NDDF
126189002	SNOMEDCT_US
126190006	SNOMEDCT_US
73454001	SNOMEDCT_US
D003894	MESH_DESCRIPTOR_UI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Desmopressin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	10702-169	TABLET	0.10 mg	ORAL	ANDA	11 sections
Desmopressin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	10702-170	TABLET	0.20 mg	ORAL	ANDA	11 sections
Desmopressin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	23155-489	TABLET	0.10 mg	ORAL	ANDA	20 sections
Desmopressin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	23155-490	TABLET	0.20 mg	ORAL	ANDA	20 sections
Desmopressin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	24208-342	SOLUTION	0.10 mg	NASAL	ANDA	27 sections
Desmopressin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	24208-342	SOLUTION	0.10 mg	NASAL	ANDA	27 sections
desmopressin acetate	HUMAN PRESCRIPTION DRUG LABEL	1	25021-460	INJECTION, SOLUTION	4 ug	INTRAVENOUS	ANDA	27 sections
desmopressin acetate	HUMAN PRESCRIPTION DRUG LABEL	1	25021-461	INJECTION, SOLUTION	40 ug	INTRAVENOUS	ANDA	27 sections
Desmopressin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	39822-6200	INJECTION, SOLUTION	4 ug	INTRAVENOUS	ANDA	27 sections
Desmopressin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	39822-6250	INJECTION, SOLUTION	4 ug	SUBCUTANEOUS	ANDA	27 sections
Desmopressin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	43598-053	INJECTION, SOLUTION	4 ug	INTRAVENOUS	ANDA	25 sections
DESMOPRESSIN ACETATE	HUMAN PRESCRIPTION DRUG LABEL	1	43598-931	INJECTION	4 ug	SUBCUTANEOUS	ANDA	13 sections
Desmopressin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	51655-461	TABLET	0.20 mg	ORAL	ANDA	11 sections
Desmopressin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	54868-1129	TABLET	0.20 mg	ORAL	ANDA	11 sections
Desmopressin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5602	SOLUTION	0.10 mg	NASAL	ANDA	21 sections
DDAVP	HUMAN PRESCRIPTION DRUG LABEL	1	55566-2200	INJECTION	4 ug	INTRAVENOUS	NDA	27 sections
DDAVP	HUMAN PRESCRIPTION DRUG LABEL	1	55566-2300	INJECTION	4 ug	INTRAVENOUS	NDA	27 sections
DDAVP	HUMAN PRESCRIPTION DRUG LABEL	1	55566-2600	TABLET	0.10 mg	ORAL	NDA	21 sections
DDAVP	HUMAN PRESCRIPTION DRUG LABEL	1	55566-2700	TABLET	0.20 mg	ORAL	NDA	21 sections
Stimate	HUMAN PRESCRIPTION DRUG LABEL	1	55566-3000	SPRAY	1.50 mg	NASAL	NDA	27 sections
Desmopressin Acetate	Human Prescription Drug Label	1	59651-249	TABLET	0.10 mg	ORAL	ANDA	20 sections
Desmopressin Acetate	Human Prescription Drug Label	1	59651-250	TABLET	0.20 mg	ORAL	ANDA	20 sections
Desmopressin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	60505-0257	TABLET	0.10 mg	ORAL	ANDA	20 sections
Desmopressin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	60505-0258	TABLET	0.20 mg	ORAL	ANDA	20 sections
DESMOPRESSIN ACETATE	HUMAN PRESCRIPTION DRUG LABEL	1	60505-0815	SPRAY	10 ug	NASAL	ANDA	25 sections
Desmopressin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	60687-721	TABLET	0.10 mg	ORAL	ANDA	20 sections
Desmopressin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	60687-721	TABLET	0.10 mg	ORAL	ANDA	20 sections
Desmopressin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	60687-732	TABLET	0.20 mg	ORAL	ANDA	20 sections
Desmopressin Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	60687-732	TABLET	0.20 mg	ORAL	ANDA	20 sections
Desmopressin Acetate	Human Prescription Drug Label	1	62756-161	SOLUTION	0.10 mg	NASAL	ANDA	22 sections

Ask DrugCentral

Try a sample question

desmopressin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: